Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Merck will face an important patent cliff by the end of the decade. The company has a plan to move beyond it. Competition from a new therapy shouldn't derail Merck's prospects. Even when we zoom ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments. Modifi Biosciences, a company formed in 2021 as a spinout of technology developed at Yale ...

Merck MRK will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively.

In a 14-1 vote, the panel moved to expand its usage recommendation for both Pfizer’s Prevnar 20 and Merck’s Capvaxive to include all adults aged 50 and older as well as adults between 19 and ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).